The oncology apoptosis modulators market, valued at USD 3.9 billion in 2022, is poised for significant growth, with ...

A PD-1/VEGF bispecific antibody is a type of cancer drug designed to target both the programmed cell death protein 1, or PD-1, on immune cells and vascular endothelial growth factor, or VEGF, on tumor ...

Researchers at Helmholtz Munich, in collaboration with colleagues at Tohoku University, have identified a specific redox protein as a critical regulator of ferroptosis - a form of regulated oxidative ...

Merck (NYSE:MRK) and LaNova Medicines announced Thursday an agreement under which the U.S. pharmaceutical giant is expected ...

A recent study unveiled a key enzyme involved in producing selenoproteins, opening new strategies for treating certain types of cancer in children.

TEVIMBRA ® (tislelizumab)is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1 ...

Merck , known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held clinical-stage biotechnology company, today announced that Merck has entered into an ...

For decades, the medical world has avidly searched for groundbreaking treatments against one of humanity’s most resilient ...

In the first category, aging is essentially an accident; an accumulation of damage and wear and tear to the body which eventually leads to death. In contrast, programmed ... mutation occurs in ...

An international research team has uncovered a new mechanism crucial to the production of cellular proteins. When this ...

"The spliceosome is composed of multiple components that secure production of functional proteins controlling cellular life," explains Dikic. "If this complex is disrupted, it can lead to the death of ...